Nektar Therapeutics (NKTR)
NKTR trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$37.92
-4.82% on the day
Market cap
$1.3B
Small cap
Revenue · 2025
$55.2M
-43.9% on 2024
Net income · 2025
-$164.0M
-296.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | NKTR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000906709 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $55.2M |
| Net income | -$164.0M |
| Operating income | -$140.1M |
| Net margin | -296.9% |
| Operating margin | -253.7% |
| Revenue growth | -43.9% |
| Cash | $15.1M |
| Total assets | $280.4M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 23.4× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-05-08 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-08-14 |
| Latest current report CURRENT REPORT | 8-K | 2026-10-01 |
| Latest proxy | DEFA14A | 2026-04-24 |
Source: SEC EDGAR submissions feed, 1,000 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -8.4% |
| 1 month | -44.6% |
| 3 months | -45.0% |
| Year to date | -12.7% |
| 1 year | -35.7% |
| From 52-week high | -63.2% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| GHRS | GH Research PLC | $18.85 | -5.84% | $1.3B |
| TYRA | Tyra Biosciences Inc. | $18.56 | -5.31% | $1.3B |
| SNDX | Syndax Pharmaceuticals Inc. | $13.95 | -15.71% | $1.2B |
| ANAB | AnaptysBio Inc. | $45.59 | -0.98% | $1.3B |
| OMER | Omeros Corporation | $18.88 | -3.82% | $1.4B |
| KARD | Kardigan Inc. | $12.97 | -9.62% | $1.2B |
| RAPP | Rapport Therapeutics Inc. | $28.99 | -3.85% | $1.4B |
| KLRA | Kailera Therapeutics Inc. | $10.77 | -4.94% | $1.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier